Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Cardiotoxicity|Risk Factor, Cardiovascular|Toxicity Due to Chemotherapy|Breast Cancer|Cardiomyopathies|Heart Failure
Interventions: DRUG: Carvedilol
Sponsor: Abramson Cancer Center at Penn Medicine